These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 34019801)

  • 21. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
    Launay O; Artaud C; Lachâtre M; Ait-Ahmed M; Klein J; Luong Nguyen LB; Durier C; Jansen B; Tomberger Y; Jolly N; Grossmann A; Tabbal H; Brunet J; Gransagne M; Choucha Z; Batalie D; Delgado A; Müllner M; Tschismarov R; Berghmans PJ; Martin A; Ramsauer K; Escriou N; Gerke C
    EBioMedicine; 2022 Jan; 75():103810. PubMed ID: 35045362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
    Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
    Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cevik M; Grubaugh ND; Iwasaki A; Openshaw P
    Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
    Sadoff J; Le Gars M; Shukarev G; Heerwegh D; Truyers C; de Groot AM; Stoop J; Tete S; Van Damme W; Leroux-Roels I; Berghmans PJ; Kimmel M; Van Damme P; de Hoon J; Smith W; Stephenson KE; De Rosa SC; Cohen KW; McElrath MJ; Cormier E; Scheper G; Barouch DH; Hendriks J; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H
    N Engl J Med; 2021 May; 384(19):1824-1835. PubMed ID: 33440088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and future nanoparticle vaccines for COVID-19.
    Vu MN; Kelly HG; Kent SJ; Wheatley AK
    EBioMedicine; 2021 Dec; 74():103699. PubMed ID: 34801965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The variants of SARS-CoV-2 and the challenges of vaccines.
    Han X; Ye Q
    J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Ella R; Reddy S; Blackwelder W; Potdar V; Yadav P; Sarangi V; Aileni VK; Kanungo S; Rai S; Reddy P; Verma S; Singh C; Redkar S; Mohapatra S; Pandey A; Ranganadin P; Gumashta R; Multani M; Mohammad S; Bhatt P; Kumari L; Sapkal G; Gupta N; Abraham P; Panda S; Prasad S; Bhargava B; Ella K; Vadrevu KM;
    Lancet; 2021 Dec; 398(10317):2173-2184. PubMed ID: 34774196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
    Singh JA; Upshur REG
    Lancet Infect Dis; 2021 Apr; 21(4):e103-e109. PubMed ID: 33306980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
    Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT
    Adv Drug Deliv Rev; 2021 May; 172():314-338. PubMed ID: 33482248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Broockman D; Kalla J; Guerrero A; Budolfson M; Eyal N; Jewell NP; Magalhaes M; Sekhon JS
    Vaccine; 2021 Jan; 39(2):309-316. PubMed ID: 33334616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.